Genentech
San Francisco, CA
Keith Dawson, DNP, MS is a Principal Portfolio Leader in Global Health Equity and Population Science for Roche/Genentech. Keith leads Clinical Development & Medical Evidence Generation strategy to broaden population specific insights and evidence generation across the drug development lifecycle for Roche. Two key projects that Keith is leading to help advance inclusive research and health equity are partnering with low and middle income countries to create a framework for scalable solutions for women with cervical and breast cancer and partnering with clinical teams to embed inclusive research tools/resources across the organization.
Keith joined Genentech in 2004 and has held positions of increasing responsibility in Product Development Clinical Operations, gRED Oncology Clinical Science and United States Medical Affairs. As a Principal Medical Science Director and US medical lead for the follicular lymphoma (FL) Disease Area Team, Keith led the medical team through the successful US launches of Rituxan Hycela in FL, CLL and DLBCL and Gazyva in 1L FL. In addition, Keith shaped the publication strategy for the National LymphoCare Study, making it one of Genentech‘s most prolific data generating oncology registries.
Keith holds a Doctorate in Nursing Practice from the University of San Francisco, an MS in Nursing from Georgetown University and a BS in Nursing from the University of Pittsburgh.
Tuesday, December 5, 2023
2:30 PM – 3:45 PM ET